VYNE Therapeutics Inc. (VYNE)
| Market Cap | 26.94M +28.3% |
| Revenue (ttm) | 454,000 -25.0% |
| Net Income | -21.46M |
| EPS | -0.50 |
| Shares Out | 33.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,243,492 |
| Open | 0.7700 |
| Previous Close | 0.7610 |
| Day's Range | 0.7550 - 0.8174 |
| 52-Week Range | 0.2805 - 1.5950 |
| Beta | 2.01 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About VYNE
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company’s lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control a... [Read more]
Financial Performance
In 2025, VYNE Therapeutics's revenue was $570,000, an increase of 13.77% compared to the previous year's $501,000. Losses were -$26.48 million, -33.52% less than in 2024.
Financial StatementsNews
VYNE Therapeutics Slides: Investor presentation
VYNE Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 14, 2026.
VYNE Therapeutics declares special cash dividend with Yarrow Bioscience merger
VYNE Therapeutics (VYNE) announced that its board of directors has declared a special cash dividend in connection with the previously announced merger with Yarrow Bioscience, pursuant to the agreement...
VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience
Aggregate cash dividend of an estimated $16.5 million, or an estimated $0.38 per share Aggregate cash dividend of an estimated $16.5 million, or an estimated $0.38 per share
VYNE Therapeutics Quarterly report: Q1 2026
VYNE Therapeutics has published its Q1 2026 quarterly earnings report on May 15, 2026.
VYNE Therapeutics Annual report: Q4 2025
VYNE Therapeutics has published its Q4 2025 annual report on February 27, 2026.
VYNE Therapeutics Transcript: M&A Announcement
VYNE and Yarrow Bioscience will merge, creating a Nasdaq-listed company focused on advancing YB-101, a first-in-class TSHR antibody for Graves' disease and TED. The combined entity is well-funded, with a strong investor syndicate and a cash runway into 2028.
VYNE Therapeutics Press release: M&A Announcement
VYNE Therapeutics issued a press release on December 17, 2025, disclosing material business information to investors.
VYNE Therapeutics, Yarrow Bioscience enter merger agreement
VYNE Therapeutics (VYNE) and Yarrow Bioscience entered into a definitive merger agreement pursuant to which the companies will combine in an all-stock transaction. Upon completion of the Merger, the c...
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE”) and Yarrow Bioscience, Inc. (“Yarrow”) today announced that they have entered into a definitive merger agreem...
VYNE Therapeutics Proxy statement: Proxy Filing
VYNE Therapeutics filed a proxy statement on November 12, 2025, providing details for shareholder voting and corporate governance matters.
VYNE Therapeutics reports Q3 EPS (17c) vs (29c) last year
Reports Q3 revenue $169k vs $121k last year. “Consistent with our focus on growing shareholder value, we have made considerable progress in evaluating a number of potential value-creating opportunitie...
VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update
Company is progressing its previously initiated strategic review evaluating a range of options to maximize shareholder value, including assessment of internal pipeline opportunities and broader strate...
VYNE Therapeutics Quarterly report: Q3 2025
VYNE Therapeutics has published its Q3 2025 quarterly earnings report on November 6, 2025.
VYNE Therapeutics Earnings release: Q3 2025
VYNE Therapeutics released its Q3 2025 earnings on November 6, 2025, summarizing the period's financial results.
VYNE Therapeutics reports Q2 EPS (13c) vs (22c) last year
Reports Q2 revenue $69,000 vs $198,000 last year. “The strength of our recent clinical and preclinical findings for VYN202 provides a compelling scientific foundation as we determine the best path…
VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update
BRIDGEWATER, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated th...
VYNE Therapeutics Quarterly report: Q2 2025
VYNE Therapeutics has published its Q2 2025 quarterly earnings report on August 14, 2025.
VYNE Therapeutics Earnings release: Q2 2025
VYNE Therapeutics released its Q2 2025 earnings on August 14, 2025, summarizing the period's financial results.
Why Is VYNE Therapeutics Stock (VYNE) Down 70% Today?
VYNE Therapeutics stock plummeted on Wednesday after a Phase 2b trial missed its primary endpoint.
VYNE Therapeutics downgraded to Neutral from Buy at BTIG
BTIG analyst Julien Harrison downgraded VYNE Therapeutics (VYNE) to Neutral from Buy with no price target after the company’s Phase 2b trial assessing repibresib in nonsegmental vitiligo did not achie...
VYNE Therapeutics downgraded at H.C. Wainwright after vitiligo trial miss
H.C. Wainwright downgraded VYNE Therapeutics (VYNE) to Neutral from Buy and removed the firm’s prior $4.50 price target after the company’s Phase 2b trial assessing repibresib in nonsegmental vitiligo...
VYNE Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis downgraded VYNE Therapeutics (VYNE) to Neutral from Buy.
VYNE says Phase 2B trial with repibresib gel did not meet primary endpoint
VYNE Therapeutics (VYNE) announced topline results from its Phase 2b trial evaluating Repibresib gel in nonsegmental vitiligo. The trial, which evaluated 177 subjects, did not meet its primary endpoin...
VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo
Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from Ba...
H.C. Wainwright ‘encouraged’ by VYNE Therapeutics VYN202 update
After VYNE Therapeutics (VYNE) provided an update on its VYN202 program following the recent FDA clinical hold on the Phase 1b trial in moderate-to-severe plaque psoriasis, H.C. Wainwright notes that…